Executives from seven leading pharmaceutical companies were called to testify before the Senate Finance Committee as part of a series of hearings on drug prices. That’s just the beginning, and other biopharma industry execs should expect a summons. It’s a no-win situation, but a little preparation can help avoid a repeat of the tobacco hearings 25 years ago. Read this Pink Sheet to find out how. Learn why changing the subject can be a smart tactic. Discover how some senators may try to lure execs into inadvertently lying–and learn how to avoid it.